Yes. Carrier screening is a type of genetic testing that can identify whether an individual carries specific genetic variants associated with certain inherited conditions, even if no symptoms are present.
This information may be useful for family planning and risk awareness. However, carrier testing does not detect all genetic conditions and does not replace medical evaluation or counselling by a qualified healthcare professional.
Genetic testing may help identify whether a child has inherited specific genetic variants associated with certain conditions. This information can support risk assessment and future healthcare planning.
However, genetic findings do not predict disease certainty and must always be interpreted together with clinical evaluation, family history, and environmental factors by a qualified healthcare professional.
The interpretation of genetic testing results can be complex, so it’s important to discuss them with a healthcare provider or geneticist who can help you understand what they mean for your health and future medical care. They will provide guidance on any preventive measures or screening recommendations based on your results. Genetic test results are not diagnostic on their own and should not be used as the sole basis for medical decisions.
No, mRNA testing is not the same as DNA testing. DNA testing analyses an individual’s genetic material (DNA) to identify genetic variations, mutations, or predispositions to certain diseases. It provides information about an individual’s inherited genetic makeup. On the other hand, mRNA testing analyses messenger RNA (mRNA) molecules, which are used to produce proteins. mRNA testing is often used to measure gene expression levels, providing insights into which genes are active or inactive in a particular tissue or sample. While both types of testing are molecular techniques used in genetics and medical diagnostics, they serve different purposes. mRNA testing reflects gene expression at a specific point in time and does not diagnose disease or confirm disease progression.
The turnaround time would be 6 weeks.
Yes, mRNA testing can detect changes in gene expression in response to cancer treatments such as chemotherapy or targeted therapy. While this information may provide insights into treatment effects, it is not a standard method for monitoring treatment response in clinical practice. Instead, its primary role lies in tumour profiling and predicting response to immunotherapy at diagnosis or during disease progression, with treatment response typically assessed through imaging, blood tests, and clinical evaluation.
是的，我们有提供提供微生物测试以控制产品质量。
支原体：
支原体检测用于检测生物样本（如细胞培养物、组织培养物和临床标本）中是否存在支原体（一种缺乏细胞壁的细菌，会对研究和生物生产造成重大干扰）。
细菌内毒素检测：
Bacterial Endotoxins Test (BET), also known as the Limulus Amebocyte Lysate (LAL) test, is a widely used assay to detect and quantify endotoxins from Gram negative bacteria in pharmaceuticals, medical devices, and other products. Endotoxins are lipopolysaccharide (LPS) components of the outer membrane of Gram-negative bacteria, which can trigger severe immune response in humans.
无菌检测：
无菌检测是一种关键的质量控制措施，用于确保药品、医疗器械、生物制剂和其他医疗保健产品的安全性、有效性和质量。
通过验证不存在活体微生物，无菌测试有助于保护患者免受感染风险或与产品污染相关的其他不良反应
Environmental Monitoring (EM) Testing
Environmental Monitoring (EM) testing is a crucial component in assessing quality of controlled environments such as cleanroom, pharma or food manufacturing and production facilities. It may involve testing multiple aspects that may affect product integrity and sterility such as air, surfaces, personnel and utensils/equipment. This helps in ensuring organization compliance with regulatory standards such as GMP, ISO 1464 and FDA.
Yes. MyGenome ensures that our microbial test methods comply with regulatory and international standards of compliance. This includes Mycoplasma Detection (EP 2.6.7), Bacterial Endotoxin (USP <85>) and Sterility (USP <71>/EP (2.6.1)/JP (4.06)).
Mycoplasma & Bacterial Endotoxin Tests: within 2 working days following sample receive date.
Sterility Testing: within 16 working days following sample receive date.
Rapid Sterility Testing: within 24 hours
EM Testing: within 7 working days following sample receive date.
The BIOAGE test is a blood-based assessment that uses PhenoAge, a scientifically developed biological age model, to estimate how your body is aging internally. Instead of relying only on your actual age, it analyses key blood markers related to metabolism, inflammation, immune function, and organ health to provide a more complete picture of your overall health. Measuring biological age is worthwhile, as it has been shown to be a good predictor of maintaining health and longevity. Determining and monitoring your biological age can help you see changes over time and understand how diet, lifestyle changes, and anti-aging treatments affect your rate of aging.
Most adults (aged 18 and above) can take the test. It’s suitable for wellness monitoring and is not intended for medical diagnosis.
A BIOAGE test is best taken once a year, but individuals making significant lifestyle changes (such as cell therapy) may test every 3 – 6 months to track improvements.
PCI testing evaluates the potential risk of herb-drug interactions (HDI) or drug-drug interactions (DDI) using an in vitro CYP450 enzyme inhibition assay. This test is suitable for drugs, herbs, supplements, functional foods and etc
PCI testing is important to ensure the safe use of drugs, herbs, supplements, and functional foods when taken together with medication.
PCI is highly relevant for:
1. Nutraceutical and herbal product manufacturers
2. Pharmaceutical including compounding pharmacy
3. Researchers in drug discovery or herbal product development
PCI testing is conducted based on internationally accepted guidelines such as those from the U.S. Food and Drug Administration (FDA).
These guidelines are widely used in the pharmaceutical and research industry to assess drug interaction risks, making PCI a scientifically credible and globally aligned approach.
The data will be securely stored within our in-house systems, using strong security measures to protect privacy and ensure data integrity.
请联系我们的营销团队 Globemedic，电话：03-2181 5665，了解有关我们实验室的价格和可用套餐的更多详细信息。
Please call 019-266 6213 to speak to a Mandarin speaking staff
We are located at Suite No. 03-04, Ground Floor, Menara See Hoy Chan, No. 374, Jalan Tun Razak, Kuala Lumpur
您可以通过以下方式联系我们：
Call / Whatsapp: 03-2161 6113
Call: 012-2665640
Email: info@mygenome.asia
是的，携带者检测是一种基因检测，可以识别您是否携带某些遗传病的基因突变，即使您自己没有任何症状。这个信息对家庭规划和了解您是否有可能将遗传病传给孩子非常有帮助。
是的，可以通过基因检测来判断孩子是否有从父母一方或双方遗传某种疾病的风险。对于可能携带基因突变的父母来说，这有助于了解孩子的风险和未来的健康需求。
基因检测结果可能比较复杂，所以最好与医生或遗传学专家讨论，他们能帮助您理解这些结果对您的健康和未来医疗的意义，并根据结果提供预防措施或筛查建议。
mRNA 测试和 DNA 测试是不同的。DNA 测试分析个人的遗传物质（DNA），以找出遗传变异、突变或对某些疾病的易感性，帮助了解个人的遗传信息。相比之下，mRNA 测试分析的是信使 RNA（mRNA）分子，这些分子在体内用来生成蛋白质。mRNA 测试常用于测量基因的表达水平，了解在特定组织或样本中哪些基因是活跃的，哪些是关闭的。尽管这两种测试都是分子生物学技术，但它们的用途不同。
结果的处理时间通常为6到10周。
是的，mRNA 测试可以用来监测癌症治疗过程中基因表达模式的变化，例如化疗或靶向治疗。这些信息有助于医生评估治疗效果，并根据需要调整治疗方案，以提高患者的治疗效果。 尽管 mRNA 测试通常不用于直接监测癌症患者的治疗反应，但它可以在诊断时或疾病进展过程中，通过分析肿瘤微环境的基因表达，帮助预测对免疫治疗的反应。 基因表达模式会随时间发生变化。如果事为了评估治疗效果，使用 mRNA 测试来监测这些变化其实并不是一个标准方法。通常，治疗效果的评估还是通过影像扫描、血液测试和临床评估等方法进行的。mRNA 测试主要用于预测免疫治疗的反应，而非直接监测治疗反应
是，我们有提供2019冠状病毒核酸检测
可以，但是预定和上门检测的报价会不同
请访问www.mygenome.asia 点击我们的服务 > 医学实验室 >分子检测 > 2019冠状病毒核酸检测
请您在上午 8点30分至10点30分之间上门进行拭子检测。
2019冠状病毒核酸检测报告将于当天下午7点前发布
2019冠状病毒核酸样品将在隔天进行检测，报告将于隔天下午7点前发布
是的，我们有提供提供微生物测试以控制产品质量。
支原体：
支原体检测用于检测生物样本（如细胞培养物、组织培养物和临床标本）中是否存在支原体（一种缺乏细胞壁的细菌，会对研究和生物生产造成重大干扰）。
细菌内毒素检测：
细菌内毒素检测 (BET)，也称为鲎变形细胞裂解物 (LAL) 检测，是一种广泛使用的检测方法，用于检测和量化药品、医疗器械和其他产品中革兰氏阴性细菌的内毒素。内毒素是革兰氏阴性细菌外膜的脂多糖 (LPS) 成分，可引起人体严重的免疫反应。
无菌检测：
无菌检测是一种关键的质量控制措施，用于确保药品、医疗器械、生物制剂和其他医疗保健产品的安全性、有效性和质量。
通过验证不存在活体微生物，无菌测试有助于保护患者免受感染风险或与产品污染相关的其他不良反应
是的。我们 MyGenome确保微生物测试方法符合法规和国际标准。这包括支原体检测 (EP 2.6.7)、细菌内毒素 (USP ) 和无菌性 (USP /EP (2.6.1)/JP (4.06))。
支原体和细菌内毒素检测：样品收到后 2 天内。
无菌检测：样品收到后 16 天内。
请联系我们的营销团队 Globemedic，电话：03-2181 5665，了解有关我们实验室的价格和可用套餐的更多详细信息。
请拨打 019-266 6213 联系可用中文沟通的工作人员。
我们的地址为：Suite No. 03-04, Ground Floor, Menara See Hoy Chan, No. 374, Jalan Tun Razak, Kuala Lumpur.
